Coronavirus vaccine: Potential drug PittCoVacc against Covid-19 develops immunity in mice

Coronavirus vaccine: Potential drug PittCoVacc against Covid-19 develops immunity in mice

The US scientists say that this vaccine which is delivered via a fingertip-sized patch induces an immune response which can prevent infection.

Researchers may have found a specific area of the coronavirus that can be targeted with therapies and drugs.

Visit BGR's homepage for more stories. Refinement of the CoroFlu vaccine concept and testing in laboratory animal models at UW-Madison is expected to take three to six months.

The safety profile, M2SR's ability to induce a strong immune response, and the ability of influenza viruses to carry sequences of other viruses make M2SR an attractive option for rapidly developing CoroFlu as a safe and effective coronavirus vaccine. In the next phase of testing, this vaccine will be tried on humans.

But the Pittsburgh research is the first study on a Covid-19 vaccine candidate to be published after critique from fellow scientists at outside institutions. The protein pieces are manufactured by a "cell factory" - multiple layers of cultured cells engineered to express the SARS-CoV-2 S protein - that can be stacked further to multiply yield.

In layman's terms, the coronavirus that causes COVID-19 uses the same "spike protein" at issue in the SARS outbreak of 2003 and MERS outbreak in 2014, said Andrea Gambotto, associate professor of surgery and co-senior author of the paper, in Pitt's press release. This is the reason to fund vaccine research, he stresses, because pandemics and epidemics are unpredictable. "You never know where the next pandemic will come from".

The vaccine is delivered through a novel approach, known as a microneedle array. Those are injected into the skin from 400 tiny needles on the micro-array.

"And it's actually pretty painless-it feels kind of like Velcro", Falo added. That's why Bill Gates said his foundation is working on no fewer than seven different candidates, creating factories that will mass-produce the final candidates.

The PittCoVacc researchers explained their method is very scalable. Purification can be done on an industrial scale, while mass production involves removing the mixture of protein and sugar with the help of a centrifuge. According to the Pittsburgh Business Times, the vaccine candidate can be mass-produced and stored at room temperature until use.

That is if the vaccine works.

Although the mice haven't been monitored long run, the researchers mentioned mice in vaccine trials for MERS-CoV "produced an adequate level of antibodies to neutralize the virus for no less than a 12 months" and indicated the antibody ranges within the mice aside of the brand new research "appear to be following the identical development". UBC's COVID-19 drug "holds promise" and is now ready for clinical testing. The Pittsburgh researchers are now applying for approval from United States regulators to start a safety trial in humans within the next few months.

Chris Smith began writing about gadgets as a hobby, and before he knew it, he was sharing his views on technology topics with readers around the world.

Related Articles